Health & Environmental Research Online (HERO)


Print Feedback Export to File
7732336 
Journal Article 
Bicifadine - Nonopioid analgesic, norepinephrine transporter inhibitor, serotonin transporter inhibitor, NMDA antagonist 
Sorbera, LA; Castaner, J; Leeson, PA 
2005 
0 
Drugs of the Future
ISSN: 0377-8282 
30 
1 
7-10 
English 
WOS:000228591400001 
Although a multitude of agents have been developed and marketed for pain management, an effective treatment for chronic pain has not yet been found. Opioid analgesics have been used for thousands of years to treat pain. However, they are not effective in the treatment of all types of chronic pain and can be associated with adverse events, tolerance and dependency. The development of nonopioid therapeutics remains a priority for researchers in the search for effective long-term therapy of chronic pain states. The 1-phenyl-3-azabicyclo[3. 1.0]hexane bicifadine is a particularly attractive novel nonopioid analgesic. This NMDA antagonist, which is also an inhibitor of both the norepinephrine and serotonin transporters, was shown to have a non-narcotic profile and potent analgesic activity in vivo. The clinical efficacy of bicifadine has also been demonstrated as a treatment for postoperative dental pain, postbunionectomy pain and chronic lower back pain. Bicifadine is undergoing phase III clinical development for the treatment of acute pain and chronic lower back pain. Copyright © 2005 PROUS SCIENCE. 
(+/-)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane